Jacobo VPM, Huerta LJG, Cravioto QP

Idioma: Español
Referencias bibliográficas: 31
Paginas: 56-63
Archivo PDF: 194.81 Kb.

RESUMEN

La relación entre el cáncer y el sistema inmunológico se ha descrito y estudiado desde el siglo XIX. El sistema inmune tiene por un lado la capacidad de detectar y eliminar células tumorales y por el otro, puede proveer un microambiente favorable para el crecimiento tumoral. Mediante el proceso de inmunoedición, el hospedero puede amoldar la inmunogenicidad de tumores a través del sistema inmune innato y adaptativo. La proliferación de células tumorales es modificada por medio de la actividad de efectores y vías de señalización pro- y antitumorales. La inmunoterapia contra el cáncer ofrece opciones terapéuticas específicas para algunas enfermedades malignas previamente intratables. Este artículo describe los procesos inmunológicos básicos de la respuesta al cáncer.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012; 23 (8): 6-9.

2. Chow MT, Möller A, Smyth MJ. Inflammation and immune surveillance in cancer. Semin Cancer Biol. 2012; 22 (1): 23-32.

3. Berraondo P, Minute L, Ajona D, Corrales L, Melero I, Pio R. Innate immune mediators in cancer: between defense and resistance. Immunol Rev. 2016; 274 (1): 290-306.

4. Hwang J et al. Las respuestas inmunológicas al cáncer. In: Méndez LJ, Tsokos GC, Escobar-Gutiérrez A, editors. Inmunología IV: aplicaciones clínicas en salud y enfermedad. Care Press. 2016. p. 861-891.

5. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-g receptors. Immunity. 1994; 1 (6): 447-456.

6. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ et al. Demonstration of an interferon-y-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA. 1998; 95 (13): 7556-7561.

7. Van den Broek ME, Kägi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK et al. Decreased tumor surveillance in perforin deficient mice. J Exp Med. 1996; 184 (5): 1781-1790.

8. Bolitho P, Street SE, Westwood JA, Edelmann W, Macgregor D, Waring P et al. Perforin-mediated supression of B-cell lymphoma. Proc Natl Acad Sci USA. 2009; 106 (8): 2723-2728.

9. Street S, Cretney E, Smyth MJ. Perforin and interferon-y activities independently control tumor initiation, growth, and metastasis. Blood. 2001; 97: 192-197.

10. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R et al. Regulation of cutaneus malignancy by gd T cells. Science. 2001; 294 (5542): 605-609.

11. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3 (11): 991-998.

12. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al. IFN and lymphocites prevent primary tumour developmentand shape tumour immunogenicity. Nature. 2001; 410 (6832): 1107-1111.

13. Browning MJ, Bodmer WF. MHC antigens and cancer: implications for T-cell surveillance. Curr Opin Immunol. 1992; 4 (5): 613-618

14. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol. 1999; 11: 68-75.

15. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006; 16 (1): 38-52.

16. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009; 182 (8): 4499-4506.

17. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004; 4 (11) 11-22.

18. Hanahan D, Weinnberg R. Hallmarks of cancer: the next generation. Cell. 2011; 144 (5): 646-674.

19. Chang MH. Cancer prevention by vaccination against hepatitis B. Recent Results Cancer Res. 2009; 181: 85-94.

20. Kenter GG, Welters MJ, Valentijn A, Lowik MJ, Berends-van der Meer DM, Vloon AP et al. Vaccination againts HPV-16 oncoproteins for vulvas intrephitelial neoplasia. N Eng J Med. 2009; 361: 1838-1847.

21. Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol. 2015; 33: 445-474.

22. Yanan L, Gang Z. Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. J Immunother. 2012; 35 (4): 299-308.

23. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation and cancer. Cell. 2010; 140 (6): 883-899.

24. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008; 454 (7203): 428-435.

25. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA. 2008; 105 (2): 652-656.

26. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in antrhacycline chemotherapy of established tumors. Cancer Res. 2011; 71 (14): 4809-4820.

27. Cui J, Chen Y, Wang HY, Wang RF. Mechanisms and pathways of innate immune activation and regulation in health and cancer. Human Vacc Immunether. 2014; 10 (11): 3270-3285.

28. Bremers AJ, Parmiani G. Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol. 2000; 34 (1): 1-25.

29. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017; 541 (7637): 321-330.

30. Finn O. Cancer immunology. N Engl J Med. 2008; 358 (25): 2704-2715.

31. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of ldo. Nat Med. 2011; 17 (9): 1094-1100.